“We found that mesothelioma patients who receive treatment in a timely fashion – and have access to specialized care, including surgery, radiation therapy and chemotherapy – have better outcomes.” -- Estelamari Rodriguez, M.D., M.P.H.
Newswise — MIAMI, FLORIDA (EMBARGOED UNTIL THURSDAY, MARCH 23, 2023, AT 11 A.M. ET) – Treatment outcomes for patients with malignant pleural mesothelioma, a rare cancer commonly known as mesothelioma, are often affected by social determinants of health and overall survival rates could be improved by addressing these health disparities and improving access to specialized care.
That’s the key takeaway from new research published March 23 by investigators at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborators, whose study appears in the journal JAMA Network Open.
“We found that mesothelioma patients who receive treatment in a timely fashion – and have access to specialized care, including surgery, radiation therapy and chemotherapy – have better outcomes,” said thoracic oncologist Estelamari Rodriguez, M.D., M.P.H., associate director of community outreach in thoracic oncology and senior author on the paper. “Unfortunately, many patients do not have access to multispecialty care in their area and that impacts their survival.”
Mesothelioma cases are rare in both the U.S. and globally, representing only 0.17 % or about 3,000 of all U.S. tumor diagnoses in 2018, the authors noted. That percentage is expected to decline further with greater awareness of the risks posed by asbestos exposure.
Consequently, many physicians have little or no experience treating mesothelioma, and those with specialized training and expertise often work at academic or other major medical centers clustered in the Northeast, South or on the West Coast. That leaves large parts of the U.S. underserved.
For this study, Rodriguez and colleagues performed a retrospective analysis of 1,389 patients from a 2017 National Cancer Database registry who were determined to have operable mesothelioma. The median age of participants was 66, with 74% being male, 89% being White and the remaining ethnicity as follows: Asian (1%), Black (3%), Hispanic (5%) and Other (2%). Median overall survival was 1.7 years.
Among the key findings was that surgery improved overall survival by 30%. Unfortunately, the authors noted, many patients were never referred for surgery, perhaps due to clinician unawareness of treatment options, biasing them toward palliative care. Race disparities were evident because Black patients were 80% more likely to die than white patients.
“If a patient gets diagnosed with non-cell lung cancer, they will probably have access to surgeons near them who feel comfortable performing that surgery,” Rodriguez said. “But oncologists in most communities have little experience with mesothelioma. This study showed that people can benefit from surgery and early multimodality treatment, but resources in the U.S. are not equally distributed.”
Other factors associated with greater survival were recent treatment, treatment at high-volume academic hospitals and greater distance to travel for treatment.
These risk factors were associated with worse overall survival, according to the study:
- Older age
- Male sex
- Black race
- Low income
- Low educational attainment
“This is where social determinants of health, including age, gender, race and income, may play a vital role in how patients are treated and explain some of the outcomes from our study,” said Rodriguez. “There is no clear link between ethnicity and the risk of mesothelioma, but there are many things about living in communities with limited access to high-level care that can explain these differences.”
Sylvester continues striving to reduce outcome disparities among mesothelioma patients. In late 2021, the center held its inaugural Miami International Mesothelioma Symposium, a virtual conference designed to educate both providers and patients about this disease. A second conference is planned for November.
Additionally, Sylvester’s expert teams are reaching out to South Florida communities to educate them about the center’s mesothelioma program and its available resources, including clinical trials, immunotherapy and other treatment options.
“We need to get past the point where physicians tell their mesothelioma patients there’s nothing they can do for them,” Rodriguez explained. “We know that patients who receive comprehensive care have better outcomes. It’s our job to make sure everyone has access.”
###
Additional authors/institutions: A full list of authors and institutions participating in this research is published with the article.
Funding: This work was supported by the Geographic Management of Cancer Health Disparities Programs (GMaP) Region 2 Trainee/Early-Stage Investigator Research Reimbursement (Dr Kareff).
Disclosures/ conflicts of interest: Dr Kareff reported receiving speaker fees from i3 Health and honorarium from the Academy for Continued Healthcare Learning, Integrity Continuing Education. Dr De Lima Lopes reported receiving stock and other ownership interests in Lucence Diagnostics and Xilis; honoraria from Boehringer Ingelheim, Blueprint Medicines, AstraZeneca, Merck and Janssen; consulting or advising fees from Pfizer and AstraZeneca; research funding from AstraZeneca, Lucence, Xilis and E.R. Squibb Sons; institutional research funding from Merck Sharp & Dohme, EMD Serono, AstraZeneca, Blueprint Medicines, Tesaro, Bavarian Nordic, NOVARTIS, G1 Therapeutics, adaptimmune, Bristol Myers Squibb, GlaxoSmithKline, AbbVie, Rgenix, Pfizer, Roche, Genentech, Lilly and Janssen; and personal fees from Boehringer Ingelheim, Pfizer, E.R. Squibb & Sons, Janssen, Seattle Genetics, Celgene, ibsen, Pharmacyclics, Merck, AstraZeneca, Seagen and Mirati Therapeutics and serving on advisory boards for Bristol Myers Squibb and Novocure. No other disclosures were reported.
DOI: 10.1001/jamanetworkopen.2023.4261
# # #
PHOTO CAPTION: “We found that mesothelioma patients who receive treatment in a timely fashion – and have access to specialized care, including surgery, radiation therapy and chemotherapy – have better outcomes.” -- Estelamari Rodriguez, M.D., M.P.H.
PHOTO CREDIT: Courtesy of Sylvester Comprehensive Cancer Center
# # #
(EMBARGOED UNTIL THURSDAY, MARCH 23, 2023, AT 11 A.M. ET)
RSS